5ZA9

uPA-BB2-50F


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.62 Å
  • R-Value Free: 0.236 
  • R-Value Work: 0.217 
  • R-Value Observed: 0.218 

wwPDB Validation   3D Report Full Report


Ligand Structure Quality Assessment 


This is version 1.0 of the entry. See complete history


Literature

6-Substituted Hexamethylene Amiloride (HMA) Derivatives as Potent and Selective Inhibitors of the Human Urokinase Plasminogen Activator for Use in Cancer.

Buckley, B.J.Aboelela, A.Minaei, E.Jiang, L.X.Xu, Z.Ali, U.Fildes, K.Cheung, C.Y.Cook, S.M.Johnson, D.C.Bachovchin, D.A.Cook, G.M.Apte, M.Huang, M.Ranson, M.Kelso, M.J.

(2018) J Med Chem 61: 8299-8320

  • DOI: 10.1021/acs.jmedchem.8b00838
  • Primary Citation of Related Structures:  
    5ZA7, 5ZA9, 5ZA8, 5ZAE, 5ZAG, 5ZAF, 5ZAH, 5ZAJ, 5ZC5

  • PubMed Abstract: 
  • Metastasis is the cause of death in the majority (∼90%) of malignant cancers. The oral potassium-sparing diuretic amiloride and its 5-substituted derivative 5 -N, N-(hexamethylene)amiloride (HMA) reportedly show robust antitumor/metastasis effects in multiple in vitro and animal models ...

    Metastasis is the cause of death in the majority (∼90%) of malignant cancers. The oral potassium-sparing diuretic amiloride and its 5-substituted derivative 5 -N, N-(hexamethylene)amiloride (HMA) reportedly show robust antitumor/metastasis effects in multiple in vitro and animal models. These effects are likely due, at least in part, to inhibition of the urokinase plasminogen activator (uPA), a key protease determinant of cell invasiveness and metastasis. This study reports the discovery of 6-substituted HMA analogs that show nanomolar potency against uPA, high selectivity over related trypsin-like serine proteases, and minimal inhibitory effects against epithelial sodium channels (ENaC), the diuretic and antikaliuretic target of amiloride. Reductions in lung metastases were demonstrated for two analogs in a late-stage experimental mouse metastasis model, and one analog completely inhibited formation of liver metastases in an orthotopic xenograft mouse model of pancreatic cancer. The results support further evaluation of 6-substituted HMA derivatives as uPA-targeting anticancer drugs.


    Organizational Affiliation

    Illawarra Health & Medical Research Institute , Wollongong , NSW 2522 , Australia.



Macromolecules
Find similar proteins by:  (by identity cutoff)  |  Structure
Entity ID: 1
MoleculeChainsSequence LengthOrganismDetailsImage
Urokinase-type plasminogen activator chain BA [auth U]253Homo sapiensMutation(s): 2 
Gene Names: PLAU
EC: 3.4.21.73
UniProt & NIH Common Fund Data Resources
Find proteins for P00749 (Homo sapiens)
Explore P00749 
Go to UniProtKB:  P00749
PHAROS:  P00749
Protein Feature View
Expand
  • Reference Sequence
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
50I (Subject of Investigation/LOI)
Query on 50I

Download Ideal Coordinates CCD File 
B [auth U]3-azanyl-5-(azepan-1-yl)-6-(1-benzofuran-2-yl)-Ncarbamimidoyl-pyrazine-2-carboxamide
C20 H23 N7 O2
FSPGYSVEHLETQR-UHFFFAOYSA-N
 Ligand Interaction
Binding Affinity Annotations 
IDSourceBinding Affinity
50I BindingDB:  5ZA9 Ki: 183 (nM) from 1 assay(s)
IC50: 530 (nM) from 1 assay(s)
Binding MOAD:  5ZA9 Ki: 183 (nM) from 1 assay(s)
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.62 Å
  • R-Value Free: 0.236 
  • R-Value Work: 0.217 
  • R-Value Observed: 0.218 
  • Space Group: H 3
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 120.51α = 90
b = 120.51β = 90
c = 42.403γ = 120
Software Package:
Software NamePurpose
REFMACrefinement
HKL-2000data reduction
HKL-2000data scaling
MOLREPphasing

Structure Validation

View Full Validation Report



Ligand Structure Quality Assessment  



Entry History & Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
The National Health and Medical Research CouncilAustraliaAPP1100432

Revision History  (Full details and data files)

  • Version 1.0: 2018-12-19
    Type: Initial release